Literature DB >> 16230338

Structural basis for reduced staphylocoagulase-mediated bovine prothrombin activation.

Rainer Friedrich1, Peter Panizzi, Shun-Ichiro Kawabata, Wolfram Bode, Paul E Bock, Pablo Fuentes-Prior.   

Abstract

Staphylocoagulase (SC) is a protein secreted by the human pathogen, Staphylococcus aureus, that activates human prothrombin (ProT) by inducing a conformational change. SC-bound ProT efficiently clots fibrinogen, thus bypassing the physiological blood coagulation pathway. The crystal structure of a fully active SC fragment, SC-(1-325), bound to human prethrombin 2 showed that the SC-(1-325) N terminus inserts into the Ile(16) pocket of prethrombin 2, thereby inducing expression of a functional catalytic site in the cognate zymogen without peptide bond cleavage. As shown here, SC-(1-325) binds to bovine and human ProT with similar affinity but activates the bovine zymogen only very poorly. By contrast to the approximately 2-fold difference in chromogenic substrate kinetic constants between human thrombin and the SC-(1-325).human (pro)thrombin complexes, SC-(1-325).bovine ProT shows a 3,500-fold lower k(cat)/K(m) compared with free bovine thrombin, because of a 47-fold increase in K(m) and a 67-fold decrease in k(cat). The SC-(1-325).bovine ProT complex is approximately 5,800-fold less active compared with its human counterpart. Comparison of human and bovine fibrinogen as substrates of human and bovine thrombin and the SC-(1-325).(pro)thrombin complexes indicates that the species specificity of SC-(1-325) cofactor activity is determined primarily by differences in conformational activation of bound ProT. These results suggest that the catalytic site in the SC-(1-325).bovine ProT complex is incompletely formed. The current crystal structure of SC-(1-325).bovine thrombin reveals that SC would dock similarly to the bovine proenzyme, whereas the bovine (pro)thrombin-characteristic residues Arg(144) and Arg(145) would likely interfere with insertion of the SC N terminus, thus explaining the greatly reduced activation of bovine ProT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230338      PMCID: PMC2292465          DOI: 10.1074/jbc.M507957200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  A surface protease and the invasive character of plague.

Authors:  O A Sodeinde; Y V Subrahmanyam; K Stark; T Quan; Y Bao; J D Goguen
Journal:  Science       Date:  1992-11-06       Impact factor: 47.728

2.  Streptokinase.

Authors:  F J Castellino; J M Sodetz; W J Brockway; G E Siefring
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

3.  Comparison of the affinities to bovine and human prothrombin of the staphylocoagulases from Staphylococcus intermedius and Staphylococcus aureus of animal origin.

Authors:  J Raus; D N Love
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

4.  Human thrombins. Production, evaluation, and properties of alpha-thrombin.

Authors:  J W Fenton; M J Fasco; A B Stackrow
Journal:  J Biol Chem       Date:  1977-06-10       Impact factor: 5.157

5.  On the mechanism of the activation of human plasminogen by recombinant staphylokinase.

Authors:  D Collen; B Schlott; Y Engelborghs; B Van Hoef; M Hartmann; H R Lijnen; D Behnke
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

6.  Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation.

Authors:  H E McCoy; C C Broder; R Lottenberg
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

7.  The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.

Authors:  W Bode; D Turk; A Karshikov
Journal:  Protein Sci       Date:  1992-04       Impact factor: 6.725

8.  Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics.

Authors:  H Brandstetter; D Turk; H W Hoeffken; D Grosse; J Stürzebecher; P D Martin; B F Edwards; W Bode
Journal:  J Mol Biol       Date:  1992-08-20       Impact factor: 5.469

9.  Activation of human prothrombin by stoichiometric levels of staphylocoagulase.

Authors:  H Hendrix; T Lindhout; K Mertens; W Engels; H C Hemker
Journal:  J Biol Chem       Date:  1983-03-25       Impact factor: 5.157

10.  The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.

Authors:  W Bode; I Mayr; U Baumann; R Huber; S R Stone; J Hofsteenge
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  10 in total

1.  Fibrinogen substrate recognition by staphylocoagulase.(pro)thrombin complexes.

Authors:  Peter Panizzi; Rainer Friedrich; Pablo Fuentes-Prior; Klaus Richter; Paul E Bock; Wolfram Bode
Journal:  J Biol Chem       Date:  2005-10-17       Impact factor: 5.157

2.  Biophysical investigation of GpIbalpha binding to thrombin anion binding exosite II.

Authors:  T Michael Sabo; Muriel C Maurer
Journal:  Biochemistry       Date:  2009-08-04       Impact factor: 3.162

3.  Spatial localization of bacteria controls coagulation of human blood by 'quorum acting'.

Authors:  Christian J Kastrup; James Q Boedicker; Andrei P Pomerantsev; Mahtab Moayeri; Yao Bian; Rebecca R Pompano; Timothy R Kline; Patricia Sylvestre; Feng Shen; Stephen H Leppla; Wei-Jen Tang; Rustem F Ismagilov
Journal:  Nat Chem Biol       Date:  2008-12       Impact factor: 15.040

4.  In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation.

Authors:  Peter Panizzi; Matthias Nahrendorf; Jose-Luiz Figueiredo; Jennifer Panizzi; Brett Marinelli; Yoshiko Iwamoto; Edmund Keliher; Ashoka A Maddur; Peter Waterman; Heather K Kroh; Florian Leuschner; Elena Aikawa; Filip K Swirski; Mikael J Pittet; Tilman M Hackeng; Pablo Fuentes-Prior; Olaf Schneewind; Paul E Bock; Ralph Weissleder
Journal:  Nat Med       Date:  2011-08-21       Impact factor: 53.440

5.  Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model.

Authors:  Christoph Guggenberger; Christiane Wolz; Julie A Morrissey; Jürgen Heesemann
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

6.  Homology Modeling of Coagulase in Staphylococcus aureus.

Authors:  Noor Asidah Mohamed; Ruzianisra Mohamed; Teoh Teow Chong
Journal:  Bioinformation       Date:  2012-05-15

7.  RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.

Authors:  Rana Jahanban-Esfahlan; Khaled Seidi; Hassan Monhemi; Amir Daei Farshchi Adli; Babak Minofar; Peyman Zare; Davoud Farajzadeh; Safar Farajnia; Ramezan Behzadi; Mehran Mesgari Abbasi; Nosratollah Zarghami; Tahereh Javaheri
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

8.  NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.

Authors:  Khaled Seidi; Rana Jahanban-Esfahlan; Hassan Monhemi; Peyman Zare; Babak Minofar; Amir Daei Farshchi Adli; Davoud Farajzadeh; Ramezan Behzadi; Mehran Mesgari Abbasi; Heidi A Neubauer; Richard Moriggl; Nosratollah Zarghami; Tahereh Javaheri
Journal:  Oncogene       Date:  2018-04-17       Impact factor: 9.867

9.  Genetic diversity of staphylocoagulase genes (coa): insight into the evolution of variable chromosomal virulence factors in Staphylococcus aureus.

Authors:  Shinya Watanabe; Teruyo Ito; Takashi Sasaki; Shanshuang Li; Ikuo Uchiyama; Kozue Kishii; Ken Kikuchi; Robert Leo Skov; Keiichi Hiramatsu
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

10.  Evolutionary and Functional Analysis of Coagulase Positivity among the Staphylococci.

Authors:  Amy C Pickering; Gonzalo Yebra; Xiangyu Gong; Mariya I Goncheva; Bryan A Wee; Alison C MacFadyen; Lukas F Muehlbauer; Joana Alves; Robyn A Cartwright; Gavin K Paterson; J Ross Fitzgerald
Journal:  mSphere       Date:  2021-08-04       Impact factor: 4.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.